Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

RFA-CA-21-047: Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)

Closed Closed December 28, 2021 Opportunity RFA-CA-21-047

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.

National Institutes of Health offered grants of up to $200,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 28, 2021.

From the official notice on Grants.gov, last changed October 26, 2021. Checked November 7, 2026.

About this NIH notice

Projects funded under RFA-CA-21-047 were run by National Cancer Institute (NCI, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.

Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-21-047 in the NIH Guide.

Other notices with this title

National Institutes of Health has posted this title under other numbers: earlier or later rounds, or the same competition for another area. Each has its own dates and may change its rules.

NoticePostedDeadlineStatus
RFA-CA-22-051October 3, 2022Closed December 28, 2022Closed

Key dates

PostedOctober 26, 2021
DeadlineDecember 28, 2021
Archived by Grants.govFebruary 2, 2022

Who can apply

This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

All 15 applicant types the notice lists

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

The HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network seeks to evaluate innovative approaches for overcoming barriers and reducing failures in the cervical cancer screening and treatment cascade for women living with HIV. The proposed multicenter network will conduct pragmatic clinical trials to evaluate the effectiveness of clinically proven interventions in intended-use settings with a goal to optimize the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. These trials will focus on the health care continuum for secondary cervical cancer prevention, i.e., increasing screening uptake, improving management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments. Data from these trials will be used to provide the necessary evidence to refine clinical practice guidelines and inform public health policy with a goal to generate crucial actionable evidence for improving cervical cancer prevention implementation programs. Six-to-eight UG1 cooperative agreement mechanism-funded Clinical Sites, led by clinical investigators and/or clinicians, will provide a pluripotent clinical infrastructure to conduct/implement multiple prevention clinical trials through the CASCADE network and interface with network grantees during concept and protocol development to provide insights and input on clinical significance and study feasibility.

Category: Education, Health.

Funded under RFA-CA-21-047 so far

NIH funded 3 projects under RFA-CA-21-047 in fiscal 2022 to 2026, at 3 institutions. The median yearly award was $214,361.

Recently funded projects
ProjectInstitutionFiscal yearAward
Implementing HIV/Cervical Cancer Prevention CASCADE Clinical Trials in Uganda (CASCADE UGANDA) UG1Makerere University Walter Reed Program Limited2026$129,367
HIV/cervical cancer cOntrol and Prevention clinical sitE in Kenya (HOPE-Kenya) UG1Emory University2026$22,297
Botswana CASCADE Clinical Trials Site UG1Brigham and Women's Hospital2026$234,775

From NIH RePORTER, which lists each project once per fiscal year it was funded. Amounts are the yearly award.

Who has won Cancer Treatment Research grants before

From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Univeristy of Texas M.D. Anderson Cancer CenterTexas144$188 million
Dana-Farber Cancer Institute, Inc.Massachusetts68$185 million
Icahn School of Medicine at Mount SinaiNew York35$179 million
Public Health InstituteCalifornia4$168 million
Fred Hutchinson Cancer CenterWashington57$156 million

Top states: California ($843 million), New York ($604 million), Massachusetts ($568 million), Texas ($444 million), Pennsylvania ($417 million).

Who has won Cancer Cause and Prevention Research grants before

From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Univeristy of Texas M.D. Anderson Cancer CenterTexas81$107 million
Sloan-Kettering Institute for Cancer ResearchNew York65$99.1 million
The Trustees of Columbia University in the City of New YorkNew York48$85.3 million
Dana-Farber Cancer Institute, Inc.Massachusetts51$83.1 million
University of North Carolina at Chapel HillNorth Carolina49$76.1 million

Top states: California ($465 million), New York ($445 million), Massachusetts ($350 million), Texas ($259 million), Pennsylvania ($175 million).

Who has won Cancer Control grants before

From fiscal 2021 to 2025, Cancer Control (93.399) awarded $814 million across 113 grant awards, an average of $7.2 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
Ecog-Acrin Medical Research Foundation, Inc.Pennsylvania1$87.9 million
NRG Oncology Foundation IncPennsylvania1$54.3 million
Alliance NCTN FoundationIllinois1$50.2 million
Oregon Health & Science UniversityOregon2$34.4 million
University of RochesterNew York1$29.8 million

Top states: Pennsylvania ($157 million), Illinois ($95.2 million), New York ($62.0 million), California ($54.0 million), Wisconsin ($44.3 million).

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is RFA-CA-21-047 still open?

No. It closed on December 28, 2021.

Who can apply for Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)?

Closed December 28, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.

How much funding is available?

Awards of up to $200,000 each.

Who has been funded under RFA-CA-21-047?

NIH RePORTER lists 3 projects funded under RFA-CA-21-047 in fiscal 2022 to 2026, at 3 institutions. The most were at Makerere University Walter Reed Program Limited, Emory University, Brigham and Women's Hospital.

Who has won Cancer Cause and Prevention Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.

Similar open grants